Clinical trial · Observational
Personalized Risk Stratification Model of Follicular Lymphoma Patients
Multilayer Model for Personalized Risk Stratification of Follicular Lymphoma Patients
NCT03436602CI-TRIAL-00097395active not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study aims at developping and validating an integrated clinico-molecular model for an accurate identification of FL patients who are progression free and progressed, respectively, at 24 months after treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Follicular Lymphoma | Follicular Lymphoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- Training cohort
- description
- Cohort of follicular lymphoma patients for the development of the multilayer risk stratification model
- label
- Validation cohort
- description
- Cohort of follicular lymphoma patients for the validation of the developed multilayer risk stratification model
Primary outcomes (1)
- measure
- Accuracy of multilayer personalized stratification model
- timeFrame
- 24 months after first line treatment
- description
- Assessment of multilayer personalized stratification model accuracy in the identification of patients who are progression free at 24 months after first line therapy plus the proportion of patients correctly identified as progressed within 24 months after first line therapy
Secondary outcomes (3)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of FL after January 1st, 2004 (chemoimmunotherapy era) * Availability of tumor material collected before initiation of medical therapy * Availability of the baseline and follow-up annotations Exclusion Criteria: * None.
References
Publications (0)
Data not yet available
No reference posted for this study.